5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

ConditionLARS - Low Anterior Resection Syndrome

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age19+

SponsorSeoul National University Hospital

About this trial

Safety \& Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

Eligibility criteria

Qualifiers

mid and low rectal cancer (AV<15cm)

stage II, III, preop long-course CCRT, then ileostomy repair

about 1~12 months after operation (no stomy)

about 1~6 months after ileostomy repair

Disqualifiers

recurred rectal cancer

stage IV

IBD

uncontrolled preoperative fecal incontinence or constipation

Trial design

Treatments tested in this trial

Ramosetron

Treatment groups

212 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Seoul National University Hospital

Lead sponsor

Source ClinicalTrials.gov